/author-service-images-prod-us-east-1.publishing.aws.arc.pub/morningstar/b76d1412-e5af-4b94-8222-8cb66fe23dbe.jpg)
Teva: Upgrading Moat and Raising Valuation on Portfolio Improvements and Deep Pipeline
We are refreshing our moat rating and fair value estimate for Teva.
Teva Pharmaceutical Industries Ltd ADR TEVA
Bulls Say, Bears Say
Bulls
Portfolio improvements from continued uptick of commercial branded drugs and launch of pipeline assets should bolster Teva's top and bottom lines for the next decade.
Bears
The majority of Teva's business lies in generic and off-patent branded drugs, which faces price and volume pressures that will be exacerbated as regulatory actions and other players in the drug supply chain exert force.
News
-
Blackstone Gives Teva $400 Million to Develop Inflammatory Bowel Disease Treatment
-
Teva Pharmaceuticals Requests Removal of Some Patents From FDA Listing After FTC Warning
-
Alkermes Files Patent Litigation Against Teva, Apotex, MSN Pharmaceuticals
-
The Israel-Iran conflict is casting a long shadow on the stock market. Here are the winners and losers.
-
Stanley Druckenmiller's Duquesne dumps Alphabet, buys more Taiwan Semi and Coupang
Trading Information
- Previous Close Price
- $34.45
- Day Range
- $33.65–34.20
- 52-Week Range
- $15.00–37.34
- Bid/Ask
- $33.90 / $33.92
- Shares Outstanding
- 1.16B
- Market Cap
- $39.52B
- Volume/Avg
- 2M / 7M
Key Statistics
- Price/Earnings (Normalized)
- 11.76
- Price/Sales
- 2.32
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Teva Pharmaceutical, based in Israel, is the world's leading generic drug manufacturer. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in two main therapeutic areas: neurology and immunology. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Large Core
- Total Number of Employees
- 32,842
- Website
- https://www.tevapharm.com
Competitors
Valuation
|
Metric
|
TEVA
|
RDY
|
VTRS
|
|---|---|---|---|
Price/Earnings (Normalized) | 11.76 | 23.62 | 6.61 |
Price/Book Value | 4.88 | 2.80 | 1.29 |
Price/Sales | 2.32 | 2.93 | 1.30 |
Price/Cash Flow | 13.42 | 15.40 | 5.66 |
Price/Earnings
TEVA
RDY
VTRS
Financial Strength
|
Metric
|
TEVA
|
RDY
|
VTRS
|
|---|---|---|---|
Quick Ratio | 0.53 | 1.26 | 0.90 |
Current Ratio | 1.01 | 1.80 | 1.60 |
Interest Coverage | 2.51 | 14.67 | −0.71 |
Quick Ratio
TEVA
RDY
VTRS
Profitability
|
Metric
|
TEVA
|
RDY
|
VTRS
|
|---|---|---|---|
Return on Assets (Normalized) | 8.61% | 9.02% | 7.58% |
Return on Equity (Normalized) | 47.02% | 13.64% | 18.88% |
Return on Invested Capital (Normalized) | 16.91% | 11.54% | 10.87% |
Return on Assets
TEVA
RDY
VTRS
Drug Manufacturers - Specialty & Generic Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Merck KGaA ADR
MKKGY
| Pvxzkzzmk | Wbjjv | $69B | |||
| Haleon PLC ADR
HLN
| Frdgwnch | Pcgg | $39B | |||
| Zoetis Inc Class A
ZTS
| Bltjxqflm | Qncz | $34B | |||
| Viatris Inc
VTRS
| Fkhlfnr | Kvfy | $19B | |||
| Elanco Animal Health Inc
ELAN
| Gyqn | Prhd | $12B | |||
| Dr Reddy's Laboratories Ltd ADR
RDY
| Hnvccmcgt | Mkby | $11B | |||
| Hims & Hers Health Inc Ordinary Shares - Class A
HIMS
| Ljvqggbw | Hqk | $7B | |||
| Prestige Consumer Healthcare Inc
PBH
| Vlkrghx | Gmxyq | $2B | |||
| Perrigo Co PLC
PRGO
| Hbthgpgbb | Fxmh | $2B |
United States